In 1971, Dr. Peter Pugliese joined the Society of Cosmetic Chemists resulting in a major career shift that would ultimately change the trajectory of his life and the skincare industry. One particular ingredient, popular in many formulations today, can be directly credited to Dr. Pugliese’s research.  Dr. Pugliese did the initial clinical studies on the first ever commercially available peptide for cosmetic use in the 1980s.  This groundbreaking research led to the expansion of peptides used in personal care products worldwide. In his studies, he discovered that copper assists in fibroblast activity and works as an antioxidant by preventing free radical damage. In addition to his pioneering research on the copper peptide, Dr. Pugliese conducted the original penetration tests of Beta Glucan on the skin in the late 80s, paving the way for cosmetic formulators today. Fast forward to 2023, and Circadia’s CEO Michael Pugliese is reviving his grandfather’s innovations but putting his own passionate spin on these industry-standard ingredients, bringing new excitement to an established ingredient profile. Enter Serum 71, a nod to the past, with an eye on the future.Serum 71 is an immune-boosting, nutrient-rich formulation with a powerful trio of tranexamic, mandelic, and azelaic acids. Also included is a second-generation Beta Glucan and Neodermyl—the next-generation copper peptide that helps build back collagen and elastin better than ever before.